E-Mail
The early prognosis of high-risk older adults for amnestic mild cognitive impairment (aMCI), using noninvasive and sensitive neuromarkers, is key for early prevention of Alzheimer s disease. A recent study, published in the
Journal of Alzheimer s Disease, by researchers at the University of Kentucky establishes what they believe is a new way to predict the risk years before a clinical diagnosis. Their work shows that direct measures of brain signatures during mental activity are more sensitive and accurate predictors of memory decline than current standard behavioral testing. Many studies have measured electrophysiological rhythms during resting and sleep to predict Alzheimer s risk. This study demonstrates that better predictions of a person s cognitive risk can be made when the brain is challenged with a task. Additionally, we learned that out of thousands of possible brain oscillation measures, left-frontal brainwaves during so-called working memory tasks are good p
E-Mail
IMAGE: Provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, January 15, 2021 The biodistribution of adeno-associated virus (AAV) gene transfer vectors can be measured in nonhuman primates using a new method. The method quantifies whole-body and organ-specific AAV capsids from 1 to 72 hours after administration. Study design and results are presented in the peer-reviewed journal
Human Gene Therapy. Click here to read the full-text article free on the
Human Gene Therapy website through February 15, 2021.
AAV capsids were labeled with I-124 and delivered using two routes of administration: intravenous and directly into the cerebrospinal fluid (CSF). Biodistribution was measured by quantitative positron emission tomography (PET) at 1, 24, 48, and 72 hours after AAV administration. Two AAV vectors - AAVrsh.10 and AAV9 - we
E-Mail
IMAGE: Wildlife biologists at the University of California, Berkeley, combined GPS location data of tagged mule deer and pronghorn antelope with satellite imagery of Wyoming fences to find out just how. view more
Credit: Image courtesy Wenjing Xu
Berkeley Each year, thousands of migratory mule deer and pronghorn antelope journey northwest from their winter homes in the Green River Basin, a grassland valley in western Wyoming, to their summer homes in the mountainous landscape near Grand Teton National Park.
But to reach their destination, these ungulates must successfully navigate the more than 6,000 kilometers (3,728 miles) of fencing that crisscrosses the region. That s enough distance to span nearly twice the length of the U.S.-Mexico border.
Loading video.
VIDEO: The larva rotates in the spherical egg to cut the chorion for hatching; 32× accelerated. view more
Credit: Takeshi Suzuki, TUAT. This was published in Eng Life Sci. 2020;20:525-534
Scientists have uncovered why a food-ingredient-based pesticide made from safflower and cottonseed oils is effective against two-spotted spider mites that attack over a thousand species of plants while sparing the mites natural predators.
An international team of scientists has uncovered how a bio-pesticide works against spider mites while sparing their natural predators.
The findings, published in the journal
Engineering in Life Sciences on October 7, 2020, could present farmers and gardeners with an eco-friendly alternative to synthetic pesticides.
AnaBios Awarded SBIR Grant by NIH/NCATS for Developing Novel Pain Therapeutics
News provided by
Share this article
Share this article
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ The National Institute of Health (NIH) and its subdivision, the National Center for Advancing Translational Sciences (NCATS), has awarded AnaBios a Phase I Small Business Innovation Research (SBIR) grant to further advance its unique human dorsal root ganglia (DRG) platform for pre-clinical drug discovery. In this NIH/NCATS-sponsored program, AnaBios will develop a battery of assays for a translational drug screening platform that will generate human-relevant data to assess the potential of a drug candidate s activity in specific pain states.